UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 26, 2016
Array BioPharma Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-16633 | 84-1460811 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 3200 Walnut Street, Boulder, Colorado 80301 |
| (Address of principal executive offices, including Zip Code) |
| (303) 381-6600 |
| (Registrant’s telephone number, including area code) |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
In this report, “Array BioPharma,” “Array,” “we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.
| Item 8.01 | Other Events. |
On September 26, 2016, Array issued a press release announcing the top-line results from Part 1 of the ongoing Phase 3 clinical trial of binimetinib and encorafenib in patients with advanced BRAF-mutant melanoma, known as the COLUMBUS trial. The study met its primary endpoint of improving progression-free survival.
A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press release announcing the top-line results from Part 1 of the ongoing Phase 3 clinical trial of binimetinib and encorafenib in patients with advanced BRAF-mutant melanoma |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: September 26, 2016 | Array BioPharma Inc. | |
| By: | /s/ Jason Haddock | |
| Jason Haddock | ||
| Chief Financial Officer | ||
3
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press release announcing the top-line results from Part 1 of the ongoing Phase 3 clinical trial of binimetinib and encorafenib in patients with advanced BRAF-mutant melanoma |